Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30115173 | 0.98 | CDK1 (0.41) | CDK1XDHDPP4PDPK1GDA | |
| SCHEMBL29745 | 0.98 | CDK1 (0.41) | CDK1XDHDPP4PDPK1GDA | |
| SCHEMBL7521321 | 0.96 | CDK1 (0.40) | CDK1XDHDPP4PDPK1GDA | |
| Hydrochloric Acid SCHEMBL28873719 | 0.96 | CDK1 (0.40) | CDK1XDHDPP4PDPK1GDA | |
| Purine SCHEMBL8019855 | 0.83 | RPS6KA5 (0.33) | CDK1 | |
| Cytosine SCHEMBL15271432 | 0.82 | PNP (0.32) | CDK1CSNK1A1CLK4PNP | |
| SCHEMBL8719270 | 0.80 | XDH (0.37) | XDHDPP4KDM4ECSNK2A1CSNK1A1 | |
| SCHEMBL8480942 | 0.79 | XDH (0.41) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| SCHEMBL30677300 | 0.79 | XDH (0.41) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| SCHEMBL37383 | 0.78 | XDH (0.38) | XDHDPP4KDM4ECSNK2A1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947824-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2011-05-24 | — | — | US | claimed |
| EP-1412369-B1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1412369-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | Ilex Oncology, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| US-6680382-B2 | COUPLING ADENINE DERIVATIVE WITH BLOCKED ARABINOFURANOSYL DERIVATIVE TO FORM 2-CHLORO-9-(2'-DEOXY-2'-FLUORO-B-ARABINOFURANOSYL)ADENINE; ANTICANCER AGENTS; VIRICIDES | ILEX PRODUCTS, INC. | 2004-01-20 | — | — | US | claimed |
| US-20030114663-A1 | Process for preparing purine nucleosides | GENZYME CORPORATION | 2003-06-19 | — | — | US | claimed |
| WO-2003011877-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20130035306-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20110282045-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-7947824-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090286971-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | GENZYME CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7528247-B2 | Process for preparing purine nucleosides | GENZYME CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1412369-B1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20050033043-A1 | Reacting a blocked 2-deoxy-alpha-D-arabinofuranosyl halide with the potassium salt of an adenine derivative to form 2-deoxy-beta-D-adenine nucleosides stereoselectively; use making antiviral or anticancer agents | GENZYME CORPORATION | 2005-02-10 | — | — | US | disclosed |
| EP-1412369-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | Ilex Oncology, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6680382-B2 | COUPLING ADENINE DERIVATIVE WITH BLOCKED ARABINOFURANOSYL DERIVATIVE TO FORM 2-CHLORO-9-(2'-DEOXY-2'-FLUORO-B-ARABINOFURANOSYL)ADENINE; ANTICANCER AGENTS; VIRICIDES | ILEX PRODUCTS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030114663-A1 | Process for preparing purine nucleosides | GENZYME CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003011877-A2 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | ILEX ONCOLOGY INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033043-A1 | Reacting a blocked 2-deoxy-alpha-D-arabinofuranosyl halide with the potassium salt of an adenine derivative to form 2-deoxy-beta-D-adenine nucleosides stereoselectively; use making antiviral or anticancer agents | SAMHD1, DCTD, DUT | CDK1 2971/4885XDH 733/4885DPP4 356/4885 |
| US-20130035306-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | SAMHD1, APRT, DCTD | CDK1 2384/4885XDH 736/4885DPP4 981/4885 |
| US-20030114663-A1 | Process for preparing purine nucleosides | SAMHD1, APRT, NUDT1 | CDK1 2463/4885XDH 822/4885DPP4 917/4885 |
| US-20110282045-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | PNP, SAMHD1, NUDT1 | CDK1 2547/4885XDH 155/4885DPP4 354/4885 |
| US-20090286971-A1 | PROCESS FOR PREPARING PURINE NUCLEOSIDES | PNP, SAMHD1, NUDT1 | CDK1 2547/4885XDH 155/4885DPP4 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.